Structure of TAK-418 (Takeda lysine-specific demethylase 1 inhibitor)

brain-penetrant LSD1 inh. for neuro. disorders

sociability improvement in vivo, completed Ph. I in HV

tranylcypromine class mechanism-based inh.

Sci. Adv., Mar. 12, 2021

Takeda Pharmaceuticals, Fujisawa, JP

The Takeda lysine-specific demethylase 1 (LSD1) inhibitor (TAK-418) is an oral CNS-penetrant clinical candidate for neurodevelopmental disorders such as autism spectrum disorder. We previously highlighted irreversible and reversible LSD1…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.